Plasma cells are terminally differentiated B lymphocytes that provide protective immunity through the continuous secretion of antibodies. Antibody‐secreting cells develop in secondary lymphoid tissue following antigen stimulation and may enter a short‐lived plasma cell population that resides primarily in the nonlymphoid area of the spleen or lymph nodes. Alternatively, antibody‐secreting cells can migrate to the bone marrow where the majority enter a long‐lived, nonproliferative population of plasma cells. Within the marrow, plasma cells situate themselves within niches where longevity is supported by factors such as
APRIL
,
IL
‐6, and
CXCL2
, provided by support cells that include
CXCL12
‐abundant reticular (
CAR
) cells, eosinophils, megakaryocytes and dendritic cells, among others.
Key Concepts
Plasma cells are terminally differentiated cells of the B lymphocyte lineage. They are committed to secreting antibody that provides an organism with protective immunity.
Plasma cells may be short‐lived, surviving only 3–5 days. Generally, these secrete lower affinity antibody. Alternatively, plasma cells may be long‐lived, surviving decades or the lifetime of an animal, secreting high‐affinity antibody resulting from somatic hypermutation within a germinal centre reaction.
Long‐lived plasma cells are primarily found in the bone marrow, where specialized niches provide contact and growth factors necessary for survival.
Multiple cell types in the niches can contribute to the extended lifespan of bone marrow plasma cells. However, plasma cells are not completely eliminated when any one cell type is depleted, suggesting that all of the supporting cells are critical and contributing components.
As B cells differentiate into plasma cells, they undergo molecular and morphological changes that better suit a highly secretory cell. They are easily identifiable via microscopy by their voluminous cytoplasm full of immunoglobulin and rough endoplasmic reticulum (RER).
Plasma cells can be identified by high surface expression of Syndecan‐1 (CD138) protein, and little to no expression of BCR, B220 or MHC class II.